Furthermore, we found that compared to the miR-575low ER+ breast cancer patients, the miR-575high ER+ breast cancer patients had a significantly poorer prognosis (Figure 1B), in contrast, expression of miR-575 was not associated with prognosis in ER- breast cancer patients (Figure 1C). Here, ESR1 is linked to breast carcinoma.